SpyGlass Pharma Q4 2025 Earnings and Corporate Update

ALISO VIEJO, Calif., March 26, 2026 SpyGlass Pharma, Inc. (Nasdaq: SGP) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside a corporate update. The company successfully completed its Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.

Key highlights from the period include positive topline 12-month data from the Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System). The trial demonstrated sustained intraocular pressure (IOP) control, with 97% of participants eliminating the need for IOP-lowering eye drops and showing improved visual performance with a favorable safety profile.

... Read on — Members only